Hemodynamic, Laboratory, and Clinical Outcomes of Hemoadsorption Therapy

NCT07679555 | Recruiting

• 1 other identifier: 169-IK/2026
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This single-center retrospective observational cohort study aims to evaluate the clinical, hemodynamic, and laboratory effects of adjunctive hemoadsorption therapy in critically ill adult patients treated in the Intensive Care Unit of Flór Ferenc Hospital, Hungary, between January 1, 2020, and May 31, 2026. Patients who received CytoSorb® or Efferon LPS® hemoadsorption therapy will be included. The study will assess changes in vasopressor requirements, hemodynamic parameters, inflammatory biomarkers, liver function tests, tissue perfusion markers, and oxygenation following hemoadsorption treatment. Clinical outcomes, including intensive care unit length of stay, all-cause mortality occurring during the patient's stay in the intensive care unit (ICU mortality), and 28-day and 90-day mortality, will also be evaluated. Data will be collected retrospectively from anonymized medical records, and no study-related interventions will be performed.

Conditions

Hemoadsorption; Vasopressor Therapy

Keywords

hemoadsorption; CytoSorb; Efferon LPS; Vasoactive Inotropic Score; Vasopressor Dependency Index; Shock reversal time; Biomarkers

Outcome Measures

Primary Outcomes (1)

• Change in Vasoactive Inotropic Score (VIS) from baseline to 24 hours after completion of hemoadsorption therapy

  The primary endpoint is the change in vasopressor and inotropic support requirements, quantified using the Vasoactive Inotropic Score (VIS), from immediately before initiation of hemoadsorption therapy (baseline) to 24 hours after completion of treatment. VIS is calculated as: VIS = dopamine (µg/kg/min) + dobutamine (µg/kg/min) + 100 × epinephrine (µg/kg/min) + 100 × norepinephrine (µg/kg/min) + 10 × milrinone (µg/kg/min) + 10 × vasopressin (U/kg/min)

  Baseline (immediately before hemoadsorption therapy) to 24 hours after completion of hemoadsorption therapy

Secondary Outcomes (4)

• Change in Vasopressor Dependency Index (VDI) from baseline to 24 hours after completion of hemoadsorption therapy

  Baseline (immediately before hemoadsorption therapy) to 24 hours after completion of hemoadsorption therapy.

• Shock Reversal Time (SRT)

  From initiation of hemoadsorption therapy until achievement of shock reversal, assessed during the first 24 hours after completion of hemoadsorption therapy.

• Change in laboratory biomarkers from baseline to immediately after and 24 hours after completion of hemoadsorption therapy

  Baseline (immediately before hemoadsorption therapy), immediately after completion of hemoadsorption therapy, and 24 hours after completion of therapy.

• Change in oxygenation (PaO₂/FiO₂ ratio) from baseline to immediately after and 24 hours after completion of hemoadsorption therapy

  Baseline (immediately before hemoadsorption therapy), immediately after completion of hemoadsorption therapy, and 24 hours after completion of therapy.

Other Outcomes (5)

• Change in Sequential Organ Failure Assessment (SOFA) score from baseline to Day 2 (24 hours after completion of hemoadsorption therapy)

  Baseline (immediately before hemoadsorption therapy) and 24 hours after completion of hemoadsorption therapy.

• Length of stay in the intensive care unit (ICU)

  From ICU admission until ICU discharge (up to 90 days).

• ICU mortality

  From ICU admission until ICU discharge (up to 90 days).

Study Arms (1)

Patients receiving hemoadsorption treatment

Critically ill patients who received hemoadsorption therapy using CytoSorb or Efferon LPS between January 1 2020 and May 31 2026

Procedure: Hemoadsorption

Interventions

Hemoadsorption PROCEDURE

Patients included in this retrospective observational study received adjunctive hemoadsorption therapy as part of routine clinical care at the discretion of the treating intensive care physicians. Hemoadsorption was performed using either the CytoSorb® or Efferon LPS® hemoadsorption cartridge, according to the clinical indication and device availability. Hemoadsorption was integrated into a continuous renal replacement therapy (CRRT) circuit. Treatment duration, number of hemoadsorption sessions, timing of therapy initiation, and concomitant intensive care interventions were determined by the treating physicians and were not influenced by the study protocol. No study-specific interventions, additional diagnostic procedures, or protocol-mandated treatments were performed.

Patients receiving hemoadsorption treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study will be retrospective. Patients who received adjunctive hemoadsorption therapy at the Department of Anesthesiology and Intensive Care of Flór Ferenc Hospital between January 1, 2020, and May 31, 2026, will be included in the study.

You may qualify if:

• \>18 years;
• CytoSorb or Efferon LPS hemoadsorption treatment,
• with available relevant pre- and post-treatment clinical and laboratory data

You may not qualify if:

• age under 18 years
• missing key demographic or outcome data;
• unknown treatment type or timing;
• data unavailable for legal or ethical reasons.

Sponsors & Collaborators

• Pest County Flór Ferenc Hospital: lead

Study Sites (1)

Pest County Flór Ferenc Hospital, Dept. of Anaesthesiology and Intensive Therapy

Kistarcsa, Pest County, 2143, Hungary

RECRUITING

Study Officials

• Zoltán Ruszkai, MD, PhD

  Pest County Flór Ferenc Hospital

  STUDY DIRECTOR

Central Study Contacts

Zoltán Ruszkai, MD, PhD

CONTACT

0036209151978; ruszkai.zoltan@florhosp.hu

Gergely Bokrétás, MD

CONTACT

bokretas.gergely@florhosp.hu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of Department of Anesthesiology and Intensive Therapy

Study Record Dates

• First Submitted: June 25, 2026
• First Posted: July 1, 2026
• Study Start: January 1, 2020
• Primary Completion: May 31, 2026
• Study Completion (Estimated): September 30, 2026
• Last Updated: July 7, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

HU (1)